New hope for frail lung cancer patients: maintenance drug aims to keep disease in check
NCT ID NCT05617963
First seen Apr 24, 2026 · Last updated May 21, 2026 · Updated 3 times
Summary
This study tests whether a drug called durvalumab can help frail patients with limited-stage small cell lung cancer keep their disease from getting worse after standard chemotherapy and radiation. About 100 participants who are older, have a weaker health status, or couldn't get full treatment will receive durvalumab every 4 weeks. The goal is to see if this maintenance therapy extends the time before the cancer progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHM - Hôpital Nord
Marseille, France
-
CARIO
Plérin, France
-
CH Saint Brieuc
Saint-Brieuc, France
-
CH de la côte Basque
Bayonne, France
-
CHI Créteil
Créteil, France
-
CHU Dupuytren
Limoges, France
-
CHU de CAEN
Caen, France
-
Centre François Baclesse
Caen, France
-
Centre George François Leclerc
Dijon, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier du Pays d'Aix
Aix-en-Provence, France
-
Centre Jean Perrin
Clermont-Ferrand, France
-
Centre Lacassagne
Nice, France
-
Centre Léon Bérard
Lyon, France
-
Centre Oscar Lambret
Lille, France
-
Centre d'Oncologie du Pays Basque
Bayonne, France
-
Centre d'oncologie Saint Yves
Vannes, France
-
Centre de Radiothérapie du Pays d'Aix
Aix-en-Provence, France
-
Clinique Belharra
Bayonne, France
-
Clinique Mutualiste de l'Estuaire
Saint-Nazaire, France
-
Groupe Hospitalier Bretagne Sud
Lorient, France
-
Hopital Nord Ouest - Villefranche sur Saône
Villefranche-sur-Saône, France
-
Hopital européen Marseille
Marseille, France
-
Hopital privé Clairval
Marseille, France
-
Hopital privé du Confluent
Nantes, France
-
Hôpital Tenon APHP
Paris, France
-
Institut Curie
Paris, France
-
Institut Godinot
Reims, France
-
Institut Paoli-Calmettes
Marseille, France
-
Institut du Cancer Avignon-Provence
Avignon, France
-
Institut régional du Cancer de Montpellier - ICM Val d'Aurelle
Montpellier, France
-
Polyclinique de Limoges -Site Clinique Chénieux
Limoges, France
Conditions
Explore the condition pages connected to this study.